4 months ago
2
Sun Pharmaceutical Industries Ltd said it has received support from the Drugs Controller General of India (DCGI) to manufacture and marketplace a generic mentation of semaglutide injection.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic value absorption successful adults arsenic an adjunct to a reduced calorie fare and accrued carnal activity.
Sun Pharma volition motorboat generic semaglutide injection nether the marque name, Noveltreat, aft the expiry of semaglutide patent successful India, it said.
The merchandise has received support from the DCGI pursuing a reappraisal of a Phase III objective proceedings conducted successful India.
Noveltreat volition beryllium disposable successful 5 dose strengths — 0.25 mg/0.5mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a attraction dose of 2.4 mg erstwhile weekly.
The merchandise is administered via an easy-to-use prefilled pen, designed to enactment convenient and close dosing.
“Obesity and diabetes person emerged arsenic 2 of the astir pressing wellness challenges confronting India and GLP-1 based therapies tin play a meaningful relation successful addressing this increasing burden. Noveltreat meets planetary prime standards and is supported by robust Indian objective grounds connected efficacy and information for value management,” said , said Kirti Ganorkar, Managing Director, Sun Pharma.
“As India’s largest pharmaceutical institution with enactment successful cardiometabolic therapies, we volition beryllium improving entree to generic semaglutide crossed the state aft the patent expiry,” helium added.
In December 2025, Sun Pharma received DCGI support for manufacturing and selling semaglutide injection for the attraction of adults with insufficiently controlled benignant 2 diabetes mellitus arsenic an adjunct to fare and exercise.
It volition beryllium launched nether the marque sanction Sematrinity, aft the expiry of semaglutide patent successful India.
